The estimated Net Worth of Jamie Mark Grooms is at least $9.44 Million dollars as of 20 September 2018. Jamie Grooms owns over 12,494 units of Axogen stock worth over $248,243 and over the last 12 years Jamie sold AXGN stock worth over $9,189,054.
Sign up
Jamie Grooms AXGN stock SEC Form 4 insiders trading
Jamie has made over 7 trades of the Axogen stock since 2017, according to the Form 4 filled with the SEC. Most recently Jamie exercised 12,494 units of AXGN stock worth $33,109 on 20 September 2018.
The largest trade Jamie's ever made was selling 95,712 units of Axogen stock on 13 February 2018 worth over $2,568,910. On average, Jamie trades about 28,160 units every 25 days since 2013. As of 20 September 2018 Jamie still owns at least 18,693 units of Axogen stock.
You can see the complete history of Jamie Grooms stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jamie Grooms's mailing address?
Jamie's mailing address filed with the SEC is 13631 PROGRESS BOULEVARD, SUITE 400, ALACHUA, FL, 32615.
Insiders trading at Axogen
Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels, and Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
What does Axogen do?
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
What does Axogen's logo look like?
Complete history of Jamie Grooms stock trades at Axogen
Axogen executives and stock owners
Axogen executives and other stock owners filed with the SEC include:
-
Eric Sandberg,
Chief Commercial Officer -
Karen Zaderej,
Chairman of the Board, President, Chief Executive Officer -
Gregory Freitag,
Director -
Angelo Scopelianos,
Vice President - Research and Development -
Peter Mariani,
Chief Financial Officer -
Maria Martinez,
Chief Human Resource Officer -
Quentin Blackford,
Independent Director -
Alan Levine,
Independent Director -
Amy Wendell,
Lead Independent Director -
Mark Gold,
Independent Director -
Guido Neels,
Independent Director -
Paul Thomas,
Director -
Brad Ottinger,
Chief Compliance Officer, General Counsel -
Isabelle Billet,
Chief Strategy and Business Development Officer -
Mark Friedman,
Vice President - Regulatory Affairs and Quality Assurance -
Erick DeVinney,
Vice President - Clinical and Translational Sciences -
Mike Donovan,
Vice President - Operations -
James E Deerfield Mgmt L.P....,
-
John P Engels,
Vice President -
Jamie Mark Grooms,
Director -
Robert James Rudelius,
Director -
Joseph M Mandato,
Director -
Shawn F Mccarrey,
SVP of Sales -
Lisa N Colleran,
Director -
Jon S. Gingrich,
Chief Commercial Officer -
Woodlands Fund Ix, L.P. Essex,
10% owner -
Kevin Leach,
Vice President Marketing -
Kathy Johnson Weiler,
Director -
William P. Mr. Burke,
Director -
Lee Robert Jr Johnston,
Chief Financial Officer -
Jill F Schiaparelli,
SVP, Bus. Strategy&Marketing -
John Frederick Harper,
Director -
Bradley Jay Hedger,
Vice President, Sales -
David K Hansen,
VP Finance & Treasurer -
Michael Patrick Donovan,
VP Operations -
Joseph A. Tyndall,
Director -
John Johnson,
Director -
Nir Naor,
CFO -
Marc A Began,
EVP and General Counsel -
Jens Kemp,
Chief Marketing Officer -
Michael D Dale,
CEO and President